Abbvie ((ABBV)), Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
AbbVie is conducting a Phase 3 clinical study to evaluate the safety and efficacy of oral ubrogepant tablets for the acute treatment of migraine in children and adolescents aged 6-17. The study, titled ‘A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Single-attack Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Oral Ubrogepant in the Acute Treatment of Migraine With or Without Aura in Children and Adolescents,’ aims to address the significant impact of migraines in this age group.
The intervention involves the use of ubrogepant, a drug already approved for adult migraine treatment, to determine its effectiveness in younger patients. Participants will receive either a low or high dose of ubrogepant or a placebo, with the option for a second dose if needed.
The study is designed as a randomized, parallel assignment with triple masking (participant, care provider, investigator) to ensure unbiased results. Its primary purpose is treatment-focused, aiming to provide a new therapeutic option for pediatric migraine sufferers.
Key dates for the study include its actual start on January 13, 2022, with the latest update submitted on July 21, 2025. These dates are crucial for tracking the study’s progress and anticipated completion.
The outcome of this study could significantly impact AbbVie’s stock performance by potentially expanding the market for ubrogepant to include pediatric patients, thus increasing revenue streams. Competitors in the migraine treatment space will be closely monitoring these developments.
The study is currently ongoing, with further details available on the ClinicalTrials portal.